We show that specified intratumoral doses of CD45-targeted IL-15 and IL-12 are retained at the tumor and TDLNs for prolonged periods of time, leading to extended pSTAT5 signaling and acquisition of a potent effector program by tumor-reactive CD8+ T cells. The gene discussed is PTPRC; the disease is neoplasm.